MOTS-c

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, specifically the 12S rRNA gene. It belongs to a family of mitochondrial-derived peptides that act as signals between mitochondria and the rest of the cell ¹. Under metabolic stress, MOTS-c moves to the cell nucleus and helps switch on protective genes, including antioxidant programs ²⁸.

Research has studied MOTS-c mostly in animals and cell models. The strongest findings are in metabolism: in mice, MOTS-c treatment prevented insulin resistance and diet-induced obesity by activating an energy-sensing enzyme called AMPK ¹. Human studies have not tested MOTS-c as a treatment. Instead, they measure naturally occurring MOTS-c levels, which are lower in people with type 2 diabetes and higher in obesity ⁹. Other preclinical work covers muscle preservation, heart protection, lung injury, and brain protection, but none of these have reached human trials ².

MOTS-c works mainly by activating AMPK, a master switch for cellular energy balance. It does this by interfering with the folate cycle and purine production, which causes a buildup of a natural AMPK activator called AICAR ¹. In muscle cells, this increases AMPK activity and leads to better glucose uptake and insulin sensitivity ¹.

MOTS-c also travels into the nucleus under stress and turns on genes with antioxidant response elements, boosting protective proteins through the Nrf2 pathway ²⁸. This dual action explains many of its effects on inflammation, mitochondrial quality, and tissue protection.

Beyond AMPK, MOTS-c directly binds to a few proteins. It activates CK2 in skeletal muscle ⁴⁷, blocks STAT3 in muscle cells to reduce muscle breakdown ³³, and helps keep KEAP1 in place to prevent a specific form of cell death called oxeiptosis ⁵⁰. Several animal studies show that removing Nrf2 cancels MOTS-c's protection ¹⁸.

The most consistent preclinical finding across independent labs is metabolic: MOTS-c improves insulin sensitivity and reduces diet-induced obesity in mice ¹. In human biomarker studies, circulating MOTS-c is lower in type 2 diabetes (pooled effect size -0.89) and higher in obesity (+0.51), which suggests the body's own levels track metabolic stress rather than a simple deficiency ¹⁰.

Other documented preclinical effects include:

• Muscle protection: In cancer cachexia mice, MOTS-c preserved quadriceps mass and reduced markers of muscle breakdown ⁷. In human muscle cells, it blocked dexamethasone-induced atrophy ⁸.
• Heart protection: In isolated rat hearts, MOTS-c reduced infarct size by 73% after ischemia-reperfusion injury ⁴. In diabetic rat hearts, it lowered inflammation and fibrosis markers ⁶.
• Lung protection: MOTS-c reduced radiation-induced lung injury in mice and improved outcomes in several lung injury models via Nrf2 ¹⁷.
• Brain and nerve protection: In animal models of sepsis and traumatic brain injury, MOTS-c improved survival and reduced brain damage ¹⁵. Small human studies show reduced MOTS-c in multiple sclerosis and depression ⁴¹.
• Antimicrobial activity: MOTS-c kills bacteria like E. coli and MRSA in lab tests and reduced infection in a mouse model ¹⁶.

These effects are mostly preclinical. No human efficacy trial of administered MOTS-c exists as of 2026 ². Human evidence is limited to observational studies of natural MOTS-c levels.

All administered-dose data for MOTS-c come from rodent and in vitro work. No human trial has tested MOTS-c directly ². The published preclinical protocols use intraperitoneal (i.p.) injection in animals, with doses spanning 0.5 to 20 mg/kg depending on the model and condition ¹.

Examples from the literature:

• In an autism model in rats, 0.5 mg/kg i.p. daily for 26 days improved behavior ²⁰.
• In radiation-induced lung injury, an engineered variant (R13A-MOTS-c) at 5 mg/kg i.p. daily for 14 days reduced damage ²⁵.
• In cancer cachexia mice, 15 mg/kg i.p. twice daily preserved muscle mass ⁷.
• In isolated rat hearts, 0.5 mg/kg in the perfusion buffer maximally reduced infarct size ⁴.

Because these are rodent doses, they cannot be directly translated to humans. Community protocols, which are not clinically validated, typically use much smaller subcutaneous doses. The most widely circulated pattern is 5 mg subcutaneously every 2-3 days for 4-6 weeks, sometimes followed by a 2-4 week break. Another common pattern is 10 mg subcutaneously three times per week for muscle or metabolic goals. Single injections above about 10 mg are uncommon in community use.

Timing in community practice often favors fasted morning dosing, because MOTS-c's AMPK pathway is suppressed after meals. Around exercise, some protocols dose before training sessions, since exercise itself raises MOTS-c levels ⁵⁴.

MOTS-c comes as a freeze-dried powder, usually in 5 mg or 10 mg vials. For research purposes, the standard diluent is bacteriostatic water, a sterile water solution with a small amount of benzyl alcohol to prevent bacterial growth. The peptide dissolves easily in water because it is highly polar, so no acidic buffers are needed.

To mix, slowly add the diluent against the vial wall and swirl gently. Avoid shaking, which can damage the peptide. Once mixed, keep the solution refrigerated at 2-8 °C and use it within 14-30 days. Discard it if it becomes cloudy or has particles.

Store unopened vials at -20 °C for long-term stability, or at 2-8 °C for up to a few months. Avoid repeated freezing and thawing; if you need to freeze the solution, split it into single-dose portions first. MOTS-c is sensitive to oxidation, especially at two methionine residues, so minimize air and light exposure. The interactive calculator below can help with dilution volumes for a given vial size and target dose.

No formal drug interaction studies exist for MOTS-c in humans. The information below comes from mechanistic preclinical work and observational biomarker data.

• Metformin: Both activate AMPK, and MOTS-c's fatty acid metabolism effects overlap with metformin's pathways ⁶⁵. Additive glucose lowering is possible in combination, though clinical co-administration has not been studied.
• Insulin and sulfonylureas: MOTS-c increases insulin sensitivity ¹, so combining with these glucose-lowering drugs could raise hypoglycemia risk in theory.
• Glucocorticoids: In human muscle cells, MOTS-c blocked dexamethasone-induced muscle atrophy, suggesting it may oppose glucocorticoid muscle wasting ⁸.
• PPARγ agonists (thiazolidinediones): MOTS-c inhibits adipogenesis by downregulating PPARγ ⁶⁶, potentially opposing TZD effects on fat tissue while overlapping on insulin sensitization.
• Radiotherapy: In lung cancer patients, radiation increased circulating MOTS-c levels, but the clinical meaning is unknown ⁶⁴.
• Nrf2-modulating supplements: MOTS-c's protective effects depend on Nrf2 ¹⁸, so combinations with Nrf2 activators like sulforaphane may be additive.
• AMPK supplements: Berberine and similar may add to MOTS-c's AMPK activation ¹.
• Antifolates: Because MOTS-c works by inhibiting the folate cycle ¹, drugs like methotrexate could theoretically interact, but no studies exist.

No interactions with anticoagulants, thyroid hormone, or antivirals have been documented. For peptide combinations, see the Stacking section.

There is no human data on whether the body develops tolerance to MOTS-c. However, the rationale for cycling comes from how MOTS-c works. It activates adaptive stress pathways like AMPK and Nrf2, which respond best to intermittent signals rather than constant stimulation. Continuous dosing could theoretically lead to compensatory downregulation ²⁹.

Community practice typically uses cycles of 4-6 weeks on, followed by 2-4 weeks off. Some protocols use 8-12 weeks for metabolic goals, and a 5-on/2-off pattern also exists. There is no human trial evidence for any cycling schedule, so these are practical conventions, not validated guidelines.

Endogenous MOTS-c levels provide some indirect support for intermittency: muscle MOTS-c remains elevated for weeks after exercise training stops ⁶¹, and circulating levels stay stable for months after weight loss ¹¹, suggesting the system adapts slowly. However, one study found that in stem cells from obese donors, MOTS-c activated metabolism but also increased senescence markers, a caution against continuous high exposure ⁴⁶.

MOTS-c is often discussed in combination with other peptides, though almost no co-administration studies exist.

• MOTS-c + Humanin (or HNG): These are complementary mitochondrial-derived peptides. In animal models, each reduced heart fibrosis and atrial fibrillation when tested separately, but the combination has not been studied ⁴⁵.
• MOTS-c + SS-31 (elamipretide): Both target mitochondrial health, and community protocols sometimes combine them. The interaction is theoretical.
• MOTS-c + BPC-157: A common recovery stack in community practice, but no published interaction data exists.
• MOTS-c + GLP-1 agonists (semaglutide): No co-administration trial. In a fatty liver model, MOTS-c was measured as a biomarker while semaglutide was the treatment ⁷⁴.
• MOTS-c + GH secretagogues (tesamorelin, ipamorelin): Distinct hormonal axes, often stacked for body composition, but no reported interaction research.

All combinations lack human trials, so the evidence is thin. The strongest mechanistic pairing appears to be with other mitochondrial-targeted compounds or with AMPK activators, but additive effects are unproven.

MOTS-c is not approved by the FDA or any other major regulatory agency for human use. It is sold through the gray market as a research peptide, outside standard pharmacy regulation ². There are no published human clinical trials, and rigorous safety data are scarce.

In sports, MOTS-c is a doping-control target. Because of its AMPK-activating effects, it falls under WADA's S0 category, which prohibits any substance without government approval for human use. A WADA-accredited laboratory has validated a mass spectrometry assay to detect synthetic MOTS-c in plasma, with a detection limit of 100 pg/mL ³⁰. This means athletes can be tested and sanctioned for MOTS-c use, even outside competition.

No enforcement actions specifically naming MOTS-c are documented, but the existence of a validated detection method indicates active monitoring ³⁰.

No human safety trial exists for MOTS-c. The only interventional safety data come from animal and ex vivo studies, which have not reported organ toxicity or deaths across a wide dose range ². In these models, MOTS-c generally shows anti-inflammatory and protective effects.

Commonly reported experiences from community use include mild injection-site reactions and same-day fatigue, but these are not documented in published trials. The theoretical concerns are more important:

• Context-dependent pro-senescence: In stem cells from obese human donors, MOTS-c activated metabolism but also increased markers of cellular aging and blunted repair function ⁴⁶.
• Tumor co-option: Mitochondrial-derived peptide programs may be exploited by tumors. Circulating MOTS-c is elevated in lung cancer and rises further after radiation ⁶⁴.
• Membrane disruption: As a cationic host-defense peptide, MOTS-c can disrupt bacterial membranes ¹⁶; at very high concentrations, host cell effects are theoretically possible but not observed.
• Hypoglycemia risk: Because MOTS-c improves insulin sensitivity ¹, it could increase the risk of low blood sugar in people taking insulin or sulfonylureas, though this has not been tested.
• Unknown long-term effects: No human data on long-term use, and gray-market product quality is unverified ².

Monitoring in research contexts typically includes fasting glucose, HbA1c, liver enzymes, and inflammation markers at baseline and periodically during use.